Rinne U K, Rinne J O
Department of Neurology, University of Turku, Finland.
Neurology. 1989 Nov;39(11 Suppl 2):78-81; discussion 95.
Therapeutic responses to Sinemet CR were studied in 37 patients with early Parkinson's disease previously treated with standard (Madopar) or controlled-release (Madopar HBS) levodopa/benserazide combinations. Patients were followed up for a 3-month period. The optimal therapeutic response of parkinsonian disability to Sinemet CR was equal to that obtained with Madopar or Madopar HBS. The optimal therapeutic dosage of Sinemet CR was equal to that of Madopar HBS but 12% higher than that of standard Madopar. However, with Sinemet CR treatment, the number of daily doses needed was significantly fewer than with both previous treatments. End-of-dose failure, which had developed in 4 patients, and peak-dose dyskinesias present in 6 patients during treatment with standard Madopar, improved significantly with Sinemet CR. Thus, Sinemet CR seems to be beneficial and useful in the treatment of early Parkinson's disease.
在37例早期帕金森病患者中研究了息宁控释片（Sinemet CR）的治疗反应，这些患者之前接受过标准（美多芭）或控释（美多芭HBS）左旋多巴/苄丝肼组合治疗。对患者进行了为期3个月的随访。帕金森病残疾对息宁控释片的最佳治疗反应与美多芭或美多芭HBS所获得的反应相当。息宁控释片的最佳治疗剂量与美多芭HBS相当，但比标准美多芭高12%。然而，使用息宁控释片治疗时，所需的每日剂量数明显少于前两种治疗方法。在标准美多芭治疗期间，4例患者出现了剂末失效，6例患者出现了峰剂量异动症，使用息宁控释片后这些症状有显著改善。因此，息宁控释片似乎对早期帕金森病的治疗有益且有用。
